Artikelempfehlungen Abstract The neuroendocrine tumors NETs are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase. They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose metabolism.
- Accepted Apr
- Intraductal papillomatosis mri
We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods.
All the patients had at least one assay per year. The dose of octreotide varied from 20 to 50 mg, monthly.
The fasting glucose insignificantly changed from baseline after 2 years. No neuroendocrine cancer age case of diabetes was registered. One case of known diabetes needed insulin but interferon therapy was also added during this time period.
The chromogranin A had sustained neuroendocrine cancer age values for all the 9 cases, marking the disease progression.
The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. The NET markers and the glucose metabolism are most useful tools in the management neuroendocrine cancer age NETs, yet they are not correlated. Neuroendocrine tumors.
MATERIALS AND METHODS: Imaging studies of 22 patients 12 men, mean age 60 years with histopathologically confirmed diagnosis, evaluated in the authors's institution during the last five years were retrospectively reviewed by two radiologists, with findings being consensually described focusing on changes observed at computed tomography. Only one typical carcinoid presented the characteristic appearance of central endobronchial nodule with distal pulmonary atelectasis, while the others were pulmonary nodules or masses. The atypical carcinoids corresponded to peripheral heterogeneous masses. One out of the three Neuroendocrine cancer age was a peripheral homogeneous mass, while the others were ill-defined and heterogeneous. The 11 SCLCs corresponded to central, infiltrating and heterogeneous masses with secondary pleuropulmonary changes.
Endocr Relat Cancer. DOI: Oberndorfer S.
Karzinoide tumoren des dunndarms. Frank Z Pathol. Carcinoid Tumors. Bellizzi AM.
Revista Romana de Medicina de Laborator
Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry.
Adv Anat Pathol. Chromogranins A B C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci.
Chromogranin A neuron specific enolase carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. CO; 8. Regul Pept.
Services on Demand
The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol. The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med.
Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.